Larry Anderson, MD, PhD, FACP
Articles
Triplet Vs Doublet Therapy for Transplant-Ineligible MM
Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.
Managing A Case of Newly-Diagnosed Transplant-Ineligible MM
A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.
Managing Adequate/Inadequate Treatment Response in MM
Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.
MRD Testing in Multiple Myeloma
Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.
Larry Anderson, MD, PhD, Discusses CAR T-Cell Therapy For Multiple Myeloma at 2021 IMW
September 10th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.
Goals of Therapy for Transplant-Ineligible MM
Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.
Larry Anderson, MD, PhD, Discussed Updated Results of the KarMMa Trial at ASCO
June 6th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 2021 ASCO Annual Meeting to talk about updated data from the KarMMa trial of CAR T-cell therapy idecabtagene vicleucel to treat patients with relapsed or refractory multiple myeloma.
